20 June 2013
Keywords: roche, extends, hiv, portfolio, nnrti, in-licensed, mv026048
Article | 29 April 2002
Roche has in-licensed MV026048, an HIV drug candidate that is expectedto enter Phase I clinical testing in 2003, from Swedish biotechnology
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 April 2002
19 June 2013
© 2013 thepharmaletter.com